- Sorrento Therapeutics (SRNE +1.5%) has received clearance from the U.S. FDA to proceed with clinical trials for the company's anti-TROP-2 antibody drug conjugate ESG-401.
- The health regulator has given clearance to proceed with trials in cancer patients with relapsed or refractory solid tumors.
- ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma, the company said.
- Separately, the company received the greenlight from the health regulator to start a Phase 2 trial designed to evaluate resiniferatoxin as a treatment for intractable pain linked to advanced cancer.
Sorrento Therapeutics gets FDA greenlight for ESG-401 cancer trials
Recommended For You
About SRNEQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRNEQ | - | - |
Sorrento Therapeutics, Inc. |